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Antisera induced by immunization of rabbits with the synthetic peptide P56/75, which has the amino
acid (aa) sequence from aa56 to aa75 of HPV16 L2, neutralize pseudovirions and raft-virions of multiple
high-risk HPV types, indicating that cross-neutralization epitopes are present in the aa56–75 region.
We generated two mouse monoclonal antibodies (MAb): MAb13B and MAb24B recognizing the regions
of aa64–73 and aa58–64, respectively. The neutralization assay using pseudovirions of HPV16, 18, 31,
33, 35, 51, 52 and 58 showed that MAb13B neutralized HPV16, 18, and 51, and MAb24B neutralized all
the types tested. The mixture of MAb13B and MAb24B neutralized HPV16, 18, and 51 pseudovirions
more efﬁciently than each of the MAbs alone. The data indicate that there are at least two cross-
neutralization epitopes in the aa56–75 region and that an antigen capable of presenting the two cross-
neutralization epitopes would be a good vaccine candidate for a broad-spectrum of HPVs.
& 2012 Elsevier Inc. All rights reserved.Introduction
Human papillomavirus (HPV) is a small nonenveloped virus
with the genome of an 8-kb double-stranded circular DNA
(Howley and Lowy, 2001). The icosahedral capsid is composed
of 360 molecules of major capsid protein L1 and 12 or more
molecules of minor capsid protein L2 (Roden et al., 1996; Volpers
et al., 1994; Buck et al., 2008). Based on the homology of
nucleotide sequence of the L1 gene, HPVs are classiﬁed into more
than 100 genotypes. Fifteen types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, 68, and 73) detectable in cervical cancer
specimens are called high-risk types (Munoz et al., 2004). HPV
type 16 (HPV16) is found in more than 50% of cervical cancer
worldwide (Munoz et al., 2004).
Since cell cultures supporting efﬁcient HPV replication are not
available, some surrogate cell-HPV particle systems are used to
analyze anti-HPV antibodies. L1 either alone or together with L2
expressed in cultured cells self-assembles into a virus-like parti-
cle (VLP) or an L1/L2-VLP, respectively, in the nucleus (Kirnbauer
et al., 1992; Zhou et al., 1991). When L1/L2-VLP is formed in a cellll rights reserved.
.
9-22 Higashi-gotanda,harboring episomal copies of a reporter plasmid, the plasmid is
packaged in the particle to form an infectious pseudovirion (PsV)
(Buck et al., 2004; Stauffer et al., 1998; Unckell et al., 1997).
Although it is not clear whether the L1/L2-VLP and the PsV are
assembled in the same way as the authentic HPV virion, they are
used as an antigen or surrogate virus for the detection of anti-HPV
antibodies or neutralizing activity, respectively (Bontkes et al.,
1999; Buck et al., 2005).
VLPs are highly immunogenic in animals and humans and
are capable of inducing type-speciﬁc neutralizing antibodies
(Giroglou et al., 2001; Harper et al., 2006; Villa et al., 2005). The
vaccines using VLPs as antigens have been developed and licensed
in many countries: the bivalent vaccine containing HPV16 and 18
VLPs (Cervarix
TM
) and the tetravalent vaccine containing HPV6, 11,
16, and 18 VLPs (Gardasil
TM
). Both vaccines efﬁciently induce
type-speciﬁc neutralizing antibodies and protect the recipients
from infection with HPVs of the vaccine-types (Harper et al.,
2006; Villa et al., 2005). Thus, one of the remaining issues to be
addressed would be the development of a prophylactic vaccine
for a broad-spectrum of HPVs.
It has been shown that L2 of human or animal papilloma-
viruses elicits antibodies cross-neutralizing PsVs in vitro (Alphs
et al., 2008; Embers et al., 2004; Gambhira et al., 2007a, 2007b;
Kawana et al., 1999; Pastrana et al., 2005; Roden et al., 2000). We
previously showed that antisera obtained by immunizing rabbits
with a synthetic peptide having the amino acid (aa) sequence of
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and cross-neutralize those of HPV18, 31, and 58 (Kondo et al.,
2007). Furthermore, it has been shown that anti-P56/75 neutra-
lizes HPV16, 18, and 31 authentic virions derived from raft-
cultures (Conway et al., 2009, 2011). These studies indicate that
the L2 segment aa56 to aa75 should contain cross-neutralization
epitopes.
Immunization of target animals with L2 peptides from some
animal papillomaviruses (bovine and cottontail rabbit) protects
the animals from experimental challenge with the corresponding
papillomaviruses (Campo et al., 1997; Christensen et al., 1991;
Embers et al., 2002; Gambhira et al., 2007a; Lin et al., 1992). Thus,
the immunizations appear to work protectively like vaccination,
despite apparent very low or often undetectable neutralizing
titers of the serum anti-L2 antibodies of the protected animals
probably due to the low sensitivity of the in vitro neutralization
assays (Jagu et al., 2011). These ﬁndings provide a basis for the
development of new HPV vaccines capable of inducing anti-L2
cross-neutralizing antibodies.
In this study we newly generated two hybridoma lines produc-
ing monoclonal antibodies (MAbs) with spleen cells of mice
immunized with P56/75 and characterized the MAbs to know
the location and the number of the cross-neutralization epitopes
in the HPV16 L2 segment aa56 to aa75. The data indicate that
there are at least two cross-neutralization epitopes in the region.Results
Subtype and aa sequences of variable regions of the MAb
We immunized Balb/c mice with the synthetic peptide P56/75
which has the aa sequence from aa56 to aa75 of HPV16 L2, and
obtained 24 hybridoma clones secreting MAbs capable of binding
to P56/75. Two MAbs bound to HPV16 L1/L2-VLP as tested by
ELISA but the others did not. The two MAbs, designated as
MAb13B and MAb24B, were further characterized. Subtype of
MAb13B was IgG1 and that of MAb24B was IgG2b.
Fig. 1 shows the aa sequences of their variable regions, which
are deduced from the nucleotide sequences of the cDNA segments
encoding the heavy- and light-chains.
Epitopes recognized by MAb13B and MAb24B
Fig. 2 shows levels of binding of the MAbs to the synthetic
peptides having parts of the aa sequence of HPV16 L2 region fromFig. 1. Amino acid sequence of the variable region of MAb13B and MAb24B. cDNA
MAb24B was cloned and sequenced. Amino acid sequence was deduced from the nuclaa53 to aa75. The peptides conjugated with BSA were ﬁxed to
wells of an ELISA plate and then the puriﬁed MAb was added to
the wells. The antibody bound to the peptide was detected by
anti-mouse IgG goat serum.
MAb13B bound to P56/75, P53/73, PA58/75, PA61/75, and
PA64/75, but not to P53/75A, P53/67A, and P53/65A. The data
indicate that the epitope for MAb13B was present within the
region from aa64 to aa73 of HPV16 L2.
MAb24B bound to P56/75, P53/73, P53/70A, PA53/67A, P53/
64A, and PA58/75, but not to PA61/75 and PA64/75. The data
indicate that the epitope for MAb24B was present within the
region from aa58 to aa64 of HPV16 L2.
Binding of MAb13B and MAb24B to L1/L2 VLP
Fig. 3 shows levels of binding of the MAbs to the L1/L2-VLPs
of HPV16, 18, 31, 33, 35, 51, 52, and 58. The serially diluted MAb
(2000 to 2 ng) was allowed to react with the L1/L2-VLP (200 ng)
ﬁxed on wells of an ELISA plate. The antibody bound to the L1/L2-
VLP was detected with anti-mouse IgG goat serum.
MAb13B bound to the L1/L2-VLPs of HPV16, 18, and 51
efﬁciently, and to those of HPV31, 33, and 58 less efﬁciently,
but not to those of HPV35 and 52. MAb24B bound to the L1/L2-
VLPs of all the types tested. MAb13B and MAb24B did not bound
to VLP lacking L2 (data not shown), strongly suggesting that the
MAbs bind to the L2 regions that are displayed on the surface of
L1/L2-VLPs.
Neutralization of pseudovirions with MAb13B and MAb24B
Fig. 4 shows levels of neutralizing activity of the MAbs against
the PsVs of HPV16, 18, 31, 33, 35, 51, 52, and 58. An anti-HPV16L1
monoclonal antibody, MAb25I, which neutralizes HPV16 PsV
efﬁciently was used as a positive control. The two-fold serially
diluted MAb solution, from 240 mg/ml to 0.47 mg/ml, was mixed
with an equal volume of the suspension of infectious PsV that
express secreted alkaline phosphatase (SEAP) and then the
mixture was inoculated to 293FT cells. Three days later the SEAP
activity of the culture medium was measured. The residual
infectivity of the PsV mixed with the MAb was shown as a
percentage of the SEAP activity to that obtained with the PsV
without MAb. Table 1 shows the 50% inhibitory concentration
(IC50) of the MAb calculated from the data.
MAb13B neutralized PsVs of HPV16, 18, and 51 with the IC50
of 1.9, 3.8, and 40.5 mg/ml, respectively, but did not neutralize
PsVs of HPV31, 33, 35, 52, and 58. MAb24B neutralized PsVs of allencoding variable region of heavy chain (VH) or light chain (VL) of MAb13B and
eotide sequence. Complementarity-determining regions (CDRs) were boxed.
Fig. 2. Mapping of epitopes for MAb13B and MAb24B. The BSA-conjugated synthetic peptide (500 ng/well) was ﬁxed on wells of an ELISA plate. The puriﬁed MAb13B
(2, 10, or 50 ng/well) or MAb24B (2, 10, or 50 ng/well) was added to the wells and the antibody bound to the peptide was detected with anti-mouse IgG goat serum.
The level of bound MAb is shown as absorbance at 450 nm.
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MAb24B (the total amount of the MAbs was indicated in Fig. 4
and Table 1) neutralized PsVs of HPV16, 18, and 51 (types
neutralized with MAb13B) more efﬁciently than each MAb alone.
The IC50 of the mixture for HPV16, 18, and 51 were two to ﬁve-
fold lower than those of each MAb alone, indicating that the
neutralization was enhanced synergistically.
The rabbit antibodies sharing binding sites with MAb13B and
MAb24B
The rabbit anti-P56/75#1 serum (Kondo et al., 2007), which
neutralizes HPV16, 18, and 31 authentic virions derived from raft-
cultures (Conway et al., 2009, 2011), contained antibodies binding to
the HPV16 L1/L2-VLP competitively with MAb13B and MAb24B
(Fig. 5). The serially diluted anti-P56/75#1 was reacted with the
HPV16 L1/L2-VLP ﬁxed on wells of an ELISA plate. Then, MAb13B or
MAb24B was allowed to bind to the antigen. Anti-P56/75#1 but not
the preimmune serum inhibited the binding of MAb13B and MAb24B
to the HPV16 L1/L2-VLP in a dose-dependent manner, suggesting that
the epitopes recognized by the immunized rabbits (Kondo et al.,
2007) were similar to those recognized by the immunized mice.Discussion
This study indicates that at least two neutralization epitopes
exist in the region from aa56 to aa75 of HPV16 L2. One epitope
(for MAb13B) exists within the region from aa64 to aa73
(SGTGGRTGYI) and the other epitope (for MAb24B) exists within
the region from aa58 to aa64 (LGIGTGS) (Figs. 2 and 6).
MAb13B bound to the L1/L2-VLPs of HPV16, 18 and 51
efﬁciently and neutralized pseudovirions of these types. HPV18
L2 has the region with the same aa sequence as that of the epitopefor MAb13B. HPV51 L2 has the region with the aa sequence of
SGSGGRTGYI, indicating that substitution of T (at aa66 of HPV16
L2) with S does not affect binding of the region with MAb13B.
MAb13B bound to the L1/L2-VLPs of HPV31, 33, and 58 less
efﬁciently and did not neutralize pseudoviruions of these types. L2s
of these types have the regions with aa sequences of the SG(T or
S)GGRTGYV, indicating that substitution of I (at aa73 of HPV16 L2)
with V reduces the afﬁnity of the region for binding with MAb13B.
MAb13B did not bind to L1/L2-VLPs of HPV35 and 52. L2s of
these types contain the regions with aa sequences of SG(T or
S)GGR(S or A)GYV, indicating that MAb13B cannot bind to the
region having further substitution of T (at aa70 of HPV16 L2)
with S or with A. Thus, T and I (at aa70 and at aa73 of HPV16 L2,
respectively) are critical for MAb13B to bind to L2 and neutralize
PsV.
MAb24B bound to the L1/L2-VLPs of all HPV types tested and
neutralized pseudovirions of these types. L2s of HPV18, 33, 51, 58
have the region with the aa sequence same as the epitope for
MAb24B. HPV31 and 33 L2s have the region with aa sequences of
LGIGSGS and HPV52 L2 has the region with aa sequence of
LGIGTGA, indicating that substitution of T (at aa62 of HPV16 L2)
with S and substitution of S (at aa64 of HPV16 L2) with A does not
affect the binding of the regions with MAb24B.
The mixture of the half amounts of MAb13B and MAb24B
(total amount of MAb was constant) neutralized HPV16, 18, and
51 more efﬁciently than each of the MAb alone, indicating that
neutralization of these types was synergistically enhanced by the
two MAbs (Table 1). It is possible that MAb13B and MAb24B bind
to one molecule of L2 simultaneously, because the core regions of
epitopes are not overlapping (Figs. 2 and 6). Probably the L2
making a complex with two antibodies greatly reduces its func-
tions necessary for infection.
The rabbit anti-P56/75#1 serum (Kondo et al., 2007),
which neutralizes HPV16, 18, and 31 authentic virions derived
Fig.3. Binding of MAb13B and MAb24B to L1/L2-VLP. The puriﬁed L1/L2-VLP composed of L1 and L2 (200 ng/well) was immobilized on wells of an ELISA plate. The
puriﬁed MAb13B (2, 20, 200, or 2000 ng/well) or MAb24B (2, 20, 200, or 2000 ng/well) was added to the well and the antibody bound to the L1/L2-VLP was detected with
anti-mouse IgG goat serum. The level of bound MAb is shown as absorbance at 450 nm after subtraction of the background.
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bodies of which binding sites were overlapped with those of
MAb13B and MAb24B (Fig. 5), indicating that the epitopes
recognized by the rabbits are very similar to those recognized
by the mice. It is possible that P56/75 may induce antibodies
similar to MAb13B and MAb24B in humans.Some cross-neutralizing anti-L2 MAbs were reported pre-
viously. MAb RG-1 recognizing the region from aa17 to aa36 of
HPV16 L2 neutralized HPV16 and 18 PsVs (Gambhira et al.,
2007b). MAbs recognizing the region from aa20 to aa38 of
HPV16 L2 neutralized PsVs of HPV16, 18, 31, 45, 58, 57, and 27
(Rubio et al., 2011). These results, together with ours, strongly
Fig. 4. Neutralization of pseudovirion (PsV) with MAb13B and MAb24B. The MAb solution was serially diluted two-fold and mixed with an equal volume of the PsV
preparation, and then inoculated to 293FT cells. The cells infected with the PsV express secreted alkaline phosphatase (SEAP). Three days later the SEAP activity of the
culture medium of the inoculated cells was measured and subtracted the background SEAP activity. The assay was done with triplicate. The percentage of the SEAP activity
to that obtained without MAb was calculated and plotted. The ﬁnal MAb concentration in the MAb/PsV mixture is presented.
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HPV16 L2, from aa17 to aa75, are essential for infectivity of HPV
and the functions may be interfered by the binding with anti-
bodies. Because the aa sequences of the N-terminal regions of
high-risk HPV L2s are similar, there are some epitopes consisting
of the common aa sequences to multiple types. Again, the antigen
capable of inducing antibodies recognizing such cross-neutrali-
zation epitopes may be a vaccine for multiple HPV types.Materials and methods
Synthetic peptides
Nine peptides that mimic some HPV16L2 segments across
aa53 to aa75 were synthesized by the Fmoc method by SCRUM
Inc. (Tokyo, Japan) or BEX Co., LTD. (Tokyo, Japan). P56/75 or P53/
73 represents a segment of aa56 to aa75 or aa53 to aa73,
Table 1
50% Inhibitory concentration (mg/ml) of MAb against PsV infection.
MAb Genotype of pseudovirion
16 18 31 33 35 51 52 58
13B 1.9 3.8 120o 120o 120o 40.5 120o 120o
24B 3.0 11.7 21.4 16.0 47.3 30.8 118.1 25.0
13B/24Ba 0.8b 1.8 24.4 14.4 120o 11.5 120o 26.1
25Ic 0.006 10o NDd ND ND ND ND ND
a Mixture of equal amounts of MAb13B and MAb24B.
b Concentration of total MAb (combined MAb13B and MAb24B).
c MAb25I is an anti-HPV16L1 monoclonal antibody.
d Not done.
Fig. 5. Inhibition of the binding of MAb13B or MAb24B to HPV16 L1/L2-VLP by
the rabbit anti-P56/75 serum. The serially diluted anti-P56/75#1 serum (Kondo
et al., 2007) or preimmune rabbit serum was reacted with the HPV16 L1/L2-VLP
(200 ng/well) ﬁxed on wells of an ELISA plate. Then MAb13B (20 ng/well) or
MAb24B (200 ng/well) was allowed to bind to the antigen and the MAb bound to
the L1/L2-VLP was detected with anti-mouse IgG goat serum. The level of bound
MAb is shown as absorbance at 450 nm after subtraction of the background.
Fig. 6. Amino acid sequences of the region from aa56 to aa75 of HPV16 L2 and
the corresponding regions of the other types. Amino acids identical to those of
HPV16 L2 are indicated by asterisk (*). The regions containing the epitopes for
MAb13B and MAb24B are boxed.
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alanine residues. P53/67A has a sequence of aa53 to aa67 plus six
alanine residues. P53/64A has a sequence of aa53 to aa64 plus
nine alanine residues. PA58/75 has three alanine residues plus a
sequence of aa58 to aa75. PA61/75 has six alanine residues plus a
sequence of aa61 to aa75. PA64/75 has nine alanine residues plus
a sequence of aa64 to aa75. P14/27, used as a negative control,has the sequence of aa14 to aa27. Cysteine was added to the
N-terminus of the peptides to conjugate with keyhole limpet
hemocyanin (KLH) or with bovine serum albumin (BSA).
MAb
Six-weeks-old BALB/c mice (3 animals) were immunized with
a mixture of P56/75 conjugated with KLH (50 mg/animal) and
Freund0s complete adjuvant subcutaneously 4 times at an interval
of 2 weeks. At 1 week after the fourth immunization, mice were
injected with 25 mg of P56/75 intraperitoneally. Splenocytes
harvested from mice at 1 week after the booster injection were
fused with mouse myeloma cells, P3U1, by the standard poly-
ethylene glycol method. The hybridomas secreting MAb capable
of binding to P56/75 conjugated with BSA were selected and then
those secreting MAb capable of binding to HPV16 L1/L2-VLP were
further selected. MAb25I is an anti-HPV16L1 monoclonal anti-
body isolated from a BALB/c mouse immunized with HPV16L1-
VLP and neutralized HPV16 PsV (our unpublished data).
MAb was puriﬁed from the ascites, which was obtained from
mice injected with the hybridoma intraperitoneally, by using Ab-
Rapid SPiN column (ProteNova, Takamatsu, Japan). The MAb was
eluted from the beads and dialyzed against phosphate-buffered
saline (PBS). The resultant MAb solution was used in the analyses.
The protein concentration of the MAb solution was measured by
comparison with standard solutions of BSA on an SDS-PAGE gel.
The subtype of the MAb was determined by the Mouse Mono-
clonal Antibody Isotyping Test Kit (AbD Serotec, Oxford, UK),
according to the manufacturer0s instruction.
Rabbit antiserum
Rabbit anti-P56/75 #1 serum was described in the previous
study (Kondo et al., 2007). The serum was obtained from the rabbit
subcutaneously injected with a mixture of P56/75 conjugated with
KLH and Freund0s complete adjuvant 4 times at 2-week interval.
S. Nakao et al. / Virology 434 (2012) 110–117116VLP and L1/L2-VLP
Expression plasmids for HPV16 L1 (p16L1h), HPV16 L2
(p16L2h), HPV18 L1 (peL1fB), and HPV18 L2 (peL2bhb) were gifts
from J.T. Schiller (NCI, USA). Expression plasmids for HPV31 L1
(p31L1h), HPV31 L2 (p31L2h), HPV51 L1 (p51L1h), HPV51 L2
(p51L2h), HPV52 L1 (p52L1h), HPV52 L2 (p52L2h), HPV58 L1
(p58L1h), and HPV58 L2 (p58L2h) were constructed previously
(Kondo et al., 2007, 2008, 2009). Expression plasmids for HPV33L1
(p33L1h), HPV33 L2 (p33L2h), HPV35 L1 (p35L1h), and HPV35 L2
(p35L2h) were similarly constructed in this study.
293FT cells (Life Technologies Corp.), a human kidney cell line
expressing SV40 T-antigen, were transfected with an L1-plasmid
(30 mg) for production of VLP or with a mixture of an L1-plasmid
(24.5 mg) and an L2-plasmid (5.5 mg) for production of the L1/L2-
VLP by using FuGENE HD (Rosch Diagnostics GmbH, Mannheim,
Germany). Fifty-eight hours later the VLP or the L1/L2-VLP was
extracted from the cells and puriﬁed as described previously
(Kondo et al., 2007).
Cloning and nucleotide sequencing of immunoglobulin variable
regions
Total RNA was extracted from the hybridoma by using the
RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany). The cDNA
segments encoding variable regions of light chain and heavy
chain of immunoglobulin were ampliﬁed by SMARTer RACE cDNA
Ampliﬁcation Kit (Clontech Laboratories, Inc., Mountain View, CA)
with primers for the constant regions of IgG1, IgG2b, and kappa
chain, whose nucleotide sequences had been described previously
(Wang et al., 2000). PCR products were cloned into pGEM-T Easy
vector (Promega Corporation, Madison, WI) and sequenced with
an ABI 3730 Genetic Analyzer (Life Technologies Corp., Carlsbad,
CA). Consensus sequences of 8 clones obtained by independent
PCR ampliﬁcation were adopted. The amino acid sequence was
deduced from the nucleotide sequence.
ELISA
The puriﬁed VLP (200 ng) or the synthetic peptide conjugated
with BSA (500 ng) in 50 ml of PBS was added to wells of an ELISA
plate (Thermo Labsystems, Franklin, MA) and incubated for over-
night at 4 1C. After washings with PBS containing 0.1% Tween-20
(Washing buffer), the wells were blocked with 5% skim milk in
PBS containing 0.1% Tween-20 (Blocking buffer) for 2 h at room
temperature (RT). The MAb diluted in Blocking buffer was added
to the wells and incubated for 2 h at RT. The horseradish
peroxidase-conjugated anti-mouse IgG goat serum (SC-2031,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) diluted at 1:2000
with Blocking buffer was added to the well and incubated for 1 h
at RT. After washings with Washing buffer a mixture of 0.01%
H2O2 and o-phenylenediamine (2 mg/ml) in 0.1 M citrate buffer
(pH4.7) was added to the wells and the absorbency at 450 nm
was measured.
Neutralization of PsV with MAb
The codon modiﬁed L1 and L2 genes of HPV16, 18, 31, 33, 35,
51, 52, and 58 were inserted into the multicloning sites A and B of
pIRES vector (Clontech Laboratories, Inc.), respectively, to obtain
plasmids (approximately 9 kb in size), pIRESL1/L2-16, -18, -31,
-33, -35, -51, -52, and -58. An expression plasmid for SEAP
(pYSEAP) was gifts from J.T. Schiller (NCI, USA).
293FT cells were transfected with a mixture of pIRESL1/L2
plasmid (16.5 mg) and pYSEAP (13.5 mg). Two days later the PsV
was extracted and puriﬁed from the cells using ‘‘AlternativeProtocol’’ described at URL: http://home.ccr.cancer.gov/lco/rip
cord.htm.
The neutralization test was carried out as described previously
(Kondo et al., 2008). Brieﬂy the mixture of serially diluted MAb
(two-fold dilution starting from 120 mg/ml) and PsV suspension
was incubated for 1 h at 4 1C and then inoculated to 293FT cells.
Three days later the SEAP activity of the culture medium was
measured by the colorimetric SEAP assay. The background OD
value was subtracted from each measurement. The relative to the
maximum OD, the measurement of the culture medium of the
cells inoculated with PsV without MAb, was calculated (%) and
plotted (Fig. 4). The MAb concentration that reduced OD to 50% of
the maximumwas calculated from the total MAb concentration in
the MAb/PsV mixture and linear percent inhibition regression line
developed and presented as IC50 in Table 1.Disclosure statement
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